Pancreatic Cancer Research

ResearcherFirst Hospital of Lanzhou UniversityActive in the last 2 years

Yulan Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3945-2157; OpenAlex author ID A5101524271. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
7
Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: 2 papers

Papers 3

  1. FOSL1 drives the malignant progression of pancreatic cancer cells by regulating cell stemness, metastasis and multidrug efflux system. Last author DOI 10.1186/s12967-025-06304-w↗
  2. PARP9 drives the malignant progression of pancreatic cancer cells by regulating apoptosis, DNA damage, and multidrug efflux systems. Last author DOI 10.3389/fcell.2025.1694345↗
  3. Pan‑cancer analysis identified ARHGAP23 as a potential biomarker for pancreatic adenocarcinoma. Last author DOI 10.3892/mco.2023.2696↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xing Wang · 1 shared paper, 2025 · strength 0.42
  2. Shuping Wang · 1 shared paper, 2025 · strength 0.28
  3. Xiaolong Liu · 1 shared paper, 2025 · strength 0.28
  4. Xueyan Zhang · 1 shared paper, 2025 · strength 0.28
  5. Pengxian Tao · 1 shared paper, 2023 · strength 0.20
  6. Xin Li · 1 shared paper, 2023 · strength 0.20
  7. Xiaolong Liu · 1 shared paper, 2023 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.